We have recently announced the 2016 dates for our International Symposium on Malignant Mesothelioma. In an effort to make it easier for the mesothelioma-affected community across the United States to access life-saving information provided directly from top experts in mesothelioma, in 2016 the Symposium will consist of three individual conferences in three major cities: Houston, […]
Research, Science and Treatments
Mary Hesdorffer, APRN, the executive director of the Mesothelioma Applied Research Foundation, was one of the 30 international speakers at the 2015 Weinman Symposium at the University of Hawaii Cancer Center.
The conference, which was sponsored by Weinman Foundation’s Honolulu chapter, the National Cancer Institute, National Institute of Environmental Health Sciences, International Association for the Study […]
The Meso Foundation is pleased to announce that Tobias Peikert, MD, of Mayo Clinic, has taken on the role of its Science Advisory Board’s chair.
The Meso Foundation’s Science Advisory Board (SAB) is comprised of doctors and researchers who work within the mesothelioma field around the world. Members of the SAB are expected to review and score […]
On October 14, the SELLAS Life Sciences Group, a biotech company leading a Phase 2 study of the WT1 vaccine, released the study’s promising data. The Meso Foundation had funded part of the Phase 1 portion of this study, the results of which prompted the Department of Defense to also award it a large grant.
The company […]
Last week, at the World Conference on Lung Cancer, Dr. Raffit Hassan presented promising data on a novel agent, anetumab ravtansine, also known as BAY 94-9343. Anetumab ravtansine is an antibody-drug conjugate directed against the target molecule mesothelin which is highly expressed on mesotheliomas.
“Anetumab ravtansine shows encouraging efficacy in patients with advanced mesothelioma which warrants […]